Reconstituted High Density Lipoprotein-Based Nanoparticles: an Overview of Applications in Regenerative Medicine, Preparation, Evaluation and Future Trends

Author(s): Xiaoyi Wang, Jianping Zhou, Wei Wang

Journal Name: Current Pharmaceutical Design

Volume 21 , Issue 12 , 2015

Become EABM
Become Reviewer


Reconstituted high density lipoprotein (rHDL) is an excellent and highly biocompatible nanovector mimicking the physical, chemical as well as physiological properties of native high density lipoprotein (HDL), and is originally widely used as the substitute in HDL related studies. Over the past decades, rHDL has increasingly been exploited into vehicles for targeted delivery of numerous drugs, therapeutic genes, etc., and is playing a more and more important role in drug delivery design for regenerative medicine. As such, a systematic review of this promising carrier will be of great importance for subsequent studies. In this article, the term “rHDL-based nanoparticles (rHDLbased NPs)” is employed to refer to rHDL and its modified form. This review highlights four aspects of rHDL-based NPs: current applications in regenerative medicine, preparation methods, conventional evaluation methods, and future trends on co-delivery of drugs for synergic effects.

Keywords: Reconstituted high density lipoprotein-based nanoparticles, drug delivery; regenerative medicine, preparation, evaluation, codelivery.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [1529 - 1544]
Pages: 16
DOI: 10.2174/1381612821666150115130102
Price: $65

Article Metrics

PDF: 47
PRC: 2